Evidence map›Paper›PMID 25341065›Full record

ArticleAmerican journal of respiratory and critical care medicine2014

α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.

Patrick Geraghty, Edward Eden, Manju Pillai, Michael Campos, Noel G McElvaney, Robert F Foronjy

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema.American journal of respiratory cell and molecular biology · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Protein Phosphatase 2A Reduces Cigarette Smoke-induced Cathepsin S and Loss of Lung Function.American journal of respiratory and critical care medicine · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Patrick Geraghty1 Division of Pulmonary and Critical Care Medicine, Mount Sinai Roosevelt Hospital, New York, New York.
Edward Eden
Manju Pillai
Michael Campos
Noel G McElvaney
Robert F Foronjy
St. Luke's-Roosevelt Hospital Center · USRoyal College of Surgeons in Ireland · IEUniversity of Miami · US

Funding

The Effects of PP2A on TNF Signaling and Smoke-Induced Lung InjuryR01HL098528 · NHLBI · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI FORONJY, ROBERT F · 2010 to 2014
$2.2M
NHLBI NIH HHS 5R01HL098528-05NHLBI NIH HHS L30 HL074905NHLBI NIH HHS R01 HL098528
6 · The paper itself

Abstract

rationaleα1-Antitrypsin (A1AT) was identified as a plasma protease inhibitor; however, it is now recognized as a multifunctional protein that modulates immunity, inflammation, proteostasis, apoptosis, and cellular senescence. Like A1AT, protein phosphatase 2A (PP2A), a major serine-threonine phosphatase, regulates similar biologic processes and plays a key role in chronic obstructive pulmonary disease.

objectivesGiven their common effects, this study investigated whether A1AT acts via PP2A to alter tumor necrosis factor (TNF) signaling, inflammation, and proteolytic responses in this disease.

methodsPP2A activity was measured in peripheral blood neutrophils from A1AT-deficient (PiZZ) and healthy (PiMM) individuals and in alveolar macrophages from normal (60 mg/kg) and high-dose (120 mg/kg) A1AT-treated PiZZ subjects. PP2A activation was assessed in human neutrophils, airway epithelial cells, and peripheral blood monocytes treated with plasma purified A1AT protein. Similarly, lung PP2A activity was measured in mice administered intranasal A1AT. PP2A was silenced in lung epithelial cells treated with A1AT and matrix metalloproteinase and cytokine production was then measured following TNF-α stimulation. MEASUREMENTS AND MAIN

resultsPP2A was significantly lower in neutrophils isolated from PiZZ compared with PiMM subjects. A1AT protein activated PP2A in human alveolar macrophages, monocytes, neutrophils, airway epithelial cells, and in mouse lungs. This activation required functionally active A1AT protein and protein tyrosine phosphatase 1B expression. A1AT treatment acted via PP2A to prevent p38 and IκBα phosphorylation and matrix metalloproteinase and cytokine induction in TNF-α-stimulated epithelial cells.

conclusionsTogether, these data indicate that A1AT modulates PP2A to counter inflammatory and proteolytic responses induced by TNF signaling in the lung.

Indexed as

Adultalpha 1-AntitrypsinAnimalsAnti-Inflammatory AgentsDisease Models, AnimalFemaleHumansInflammationLungMaleMiceMiddle AgedNeutrophilsProtein Phosphatase 2Pulmonary Disease, Chronic ObstructiveSerine Proteinase Inhibitorsalpha 1-AntitrypsinAnti-Inflammatory AgentsProtein Phosphatase 2Serine Proteinase InhibitorsTumor Necrosis Factor-alphacell signalinginflammationphosphorylationPP2Aα1-antitrypsin

Identifiers

PMID25341065
PMCPMC4315812
OpenAlexW1965307552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.